Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AN2 Therapeutics, Inc. (Nasdaq: ANTX) recently reported its financial results for 2022, marking a transformative year as the company transitioned to public status. The pivotal Phase 2/3 trial for epetraborole, targeting treatment-refractory Mycobacterium avium complex (MAC) lung disease, is currently progressing with nearly 60 clinical sites globally, including newly opened sites in Japan, South Korea, and Australia. The company received significant funding of up to $17.8M for developing epetraborole against melioidosis. In 2022, R&D expenses increased to $29.5M, while the net loss reached $41M. AN2's cash reserves are projected to last through mid-2024, supporting ongoing clinical efforts.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference in Boston, where CEO Eric Easom will join an Infectious Disease panel on March 7. The second event is the Oppenheimer 33rd Annual Healthcare Conference, with Easom providing a corporate overview on March 14. Webcasts will be accessible on the AN2 Therapeutics website, with archived replays available for 30 days post-event. Their lead candidate, epetraborole, is being studied for NTM lung disease.